Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX, USA.
Department of Medicine, Division of Hematology/Oncology, University of Texas Health Science Center San Antonio, San Antonio, TX, USA.
Future Oncol. 2019 May;15(14):1641-1653. doi: 10.2217/fon-2018-0936. Epub 2019 Mar 20.
Eribulin is a novel microtubule inhibitor with mitotic and nonmitotic mechanisms of action. Both pooled and subgroup analyses from large-scale Phase III clinical trials demonstrated that eribulin has substantial activity in patients with pretreated (anthracycline and a taxane) advanced or metastatic breast cancer. We review recent pharmacological and clinical findings pertaining to eribulin use in metastatic breast cancer - particularly highlighting eribulin in difficult-to-treat and aggressive disease, and safety data in specific patient populations. Additionally, recent advancements in our understanding of the mechanism of action of eribulin and potential future directions for its clinical development are discussed. Ongoing studies of eribulin in combination with immunotherapies and established cytotoxic agents may help shape the future landscape of breast cancer treatment.
依维莫司是一种新型的微管抑制剂，具有有丝分裂和非有丝分裂的作用机制。来自大型三期临床试验的汇总分析和亚组分析表明，依维莫司在预处理（蒽环类药物和紫杉烷类药物）的晚期或转移性乳腺癌患者中具有显著的活性。我们综述了依维莫司在转移性乳腺癌中的近期药理学和临床研究结果 - 特别强调了依维莫司在难治性和侵袭性疾病中的应用，以及特定患者人群的安全性数据。此外，我们对依维莫司作用机制的理解的最新进展和其临床开发的潜在未来方向进行了讨论。依维莫司与免疫疗法和已确立的细胞毒性药物联合治疗的正在进行的研究可能有助于塑造乳腺癌治疗的未来格局。
